Introduktion af aktieincitamentsprogram
Meddelelse nr. 1 - 2023
til Nasdaq Copenhagen
19. januar 2023
Introduktion af aktieincitamentsprogram
Bestyrelsen i Brødrene A. & O. Johansen A/S har i dag besluttet at introducere et 3-årigt aktieincitamentsprogram, hvor udvalgte kommercielle ledere (”Deltagerne”) tildeles betingede gratisaktier (”Betingede Gratisaktier”) vederlagsfrit. Tildelingen omfatter ikke medlemmer af selskabets direktion eller bestyrelse.
Formålet med programmet er navnligt at (i) sikre sammenfaldende interesser mellem Deltagerne og selskabets aktionærer, (ii) motivere og understøtte en fastholdelse af Deltagernes fortsatte ansættelse, samt (iii) fremme en langsigtet værdiskabelse i selskabet.
Bestyrelsen har i alt tildelt Deltagerne 56.935 Betingede Gratisaktier. Den nuværende værdi af hver betinget gratisaktie er opgjort til DKK 91,28 svarende til den volumenvægtede gennemsnitskurs for Brødrene A. & O. Johansen A/S B-aktier i 10 handelsdage forud for introduktionstidspunktet. Den samlede dagsværdi af de tildelte Betingede Gratisaktier under programmet er opgjort til i alt DKK 5.197.027.
De Betingede Gratisaktier optjenes med 1/3 hvert år fra introduktionstidspunktet indtil alle Betingede Gratisaktier er optjent, svarende til at alle tildelte Betingede Gratisaktier optjenes over en samlet modningsperiode på i alt 3 år. Efter udløbet af modningsperioden i 2026 giver hver betinget gratisaktie Deltageren en ret til at modtage én Brødrene A. & O. Johansen A/S B-aktie med en nominel værdi på DKK 1. Optjening samt endelig levering af aktier i selskabet er i udgangspunktet betinget af, at Deltageren fortsat er ansat i A. & O. koncernen i henhold til nærmere fastsatte good og bad leaver vilkår.
Tildelingen af Betingede Gratisaktier har ingen udvandingseffekt for eksisterende aktionærer, da leveringen af aktier under programmet afdækkes via selskabets beholdning af egne aktier.
Med venlig hilsen
Brødrene A. & O. Johansen A/S
Niels A. Johansen
Adm. direktør
Vedhæftet fil
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
23/2024・Trifork Group AG – Shareholders approve all resolutions at the Annual General Meeting 202419.4.2024 17:34:19 CEST | Press release
Company announcement no. 23 / 2024 Schindellegi, Switzerland – 19 April 2024 Shareholders approve all resolutions at the Annual General Meeting 2024 The shareholders of Trifork Group AG (“Trifork“) today approved all resolutions proposed by the Board of Directors at Trifork’s Annual General Meeting 2024 (the “AGM“) which was held at Grabenstrasse 2, 6430 Baar, Switzerland. Dividend payment The shareholders approved the Board of Directors’ proposal to pay a gross dividend of EUR 0.10 per share (equivalent to CHF 0.10 per share) by making a payout from capital contribution reserves to the shareholders. The total gross dividend paid out amounts to CHFk 1,932, equivalent to DKKk 14,809, as calculated per the exchange rate published by the Swiss Federal Customs Administration as of 19 April 2024. The payout from capital contribution reserves is declared in CHF and paid out in DKK. Composition of the Board of Directors The shareholders re-elected Julie Galbo as Chairperson of the Board of Di
Havila Shipping ASA: Årsrapport 202319.4.2024 17:06:25 CEST | Pressemelding
Styret i Havila Shipping ASA har i dag godkjent regnskap og årsrapport for 2023 for konsern og morselskap. Resultatregnskap og balanser er i samsvar med foreløpig regnskap offentliggjort 27. februar 2024. Kontakter: Administrerende direktør Njål Sævik, +47 909 35 722 Finansdirektør Arne Johan Dale, +47 909 87 706 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no
Havila Shipping ASA : Annual Report 202319.4.2024 17:06:25 CEST | Press release
Today, the Board of Directors of Havila Shipping ASA has approved the financial statements for 2023 for both the Group and the parent company. The accounts are in line with preliminary accounts released on 27 February 2024. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722 Chief Financial Officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons19.4.2024 17:05:00 CEST | Press release
Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and
Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 202419.4.2024 17:00:00 CEST | Press release
Company announcement – No. 22 / 2024 Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of long-term incentive programs (the “LTIP”) for Zealand's Board of Directors, Corporate Management and employees in accordance with Zealand's remuneration policy and overall guidelines for incentive pay, as adopted at the annual general meeting held on March 20, 2024 (“Remuneration Policy”). Long-term incentive program Zealand has made the following awards in its long-term incentive plan. It has awarded: 20,497 restricted stock units ("RSUs") to Zealand's Board of Directors 52,777 performance stock units ("PSUs") and 52,777 RSUs have been awarded to Zealand’s Corporat